Why is the Polynovo (ASX:PNV) share price having such a tough time of late?

What's up with medical device company's shares? We take a closer look

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Polynovo Ltd (ASX: PNV) share price has been on a trending decline over the past 6 months, falling by 40%. This comes as the medical device company has been relatively quiet on the news front.

At Tuesday's closing bell, Polynovo shares finished the day up 3.61% to $1.865.

A doctor in a white coat with a stethoscope around her neck holds her hands upwards as if to ask 'why' as she sits at her desk and looks at her computer.

Image source: Getty Images

What's been happening with Polynovo lately?

While no new announcements have been released since last month, Polynovo has been busy progressing its BARDA-funded burn study. BARDA is an acronym for the United States-based Biomedical Advanced Research and Development Authority.

The trial spans 20 United States and 5 Canadian burn centres for the clinical study of NovoSorb BTM. Polynovo aims for its NovoSorb BTM to be used as a standard of care in burn patients.

In addition, the company's chief operating officer, Dr Anthony Kaye, resigned from his position last month. The Polynovo share price fell more than 10% that week after it was revealed Dr Kaye was returning to CSL Limited (ASX: CSL) in a more senior role.

However, Polynovo's path to profitability is growing stronger following its robust FY21 results.

The company experienced growth across key financial metrics which led it to break even for the first time in its history.

Polynovo expects continued momentum to run into FY22 across a number of geographical markets. These include the United States, Europe, the United Kingdom, the Middle East, Asia, Australia, and New Zealand.

Its NovoSorb graft is expected to see sales surge in FY22, with "70% of burns centres now having purchased" the product.

Furthermore, Polynovo intends to expand its headcount and enter new markets, particularly within the European Union.

Nonetheless, the Polynovo share price has slumped. This is possibly due to bearish sentiment by investors which has caused selling pressure.

Polynovo share price summary

Despite today's gain, Polynovo shares are down more than 25% for the past 12 months, and 50% in 2021.

Polynovo has a market capitalisation of roughly $1.24 billion and has approximately 661.4 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

young female doctor with digital tablet looking confused.
Healthcare Shares

Telix shares are tumbling. Is the stock finally at fair value?

Telix's sell-off reflects valuation, competition, and heightened growth expectations.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Why I'd buy Medibank shares for the dividend yield

Medibank is providing investors with very healthy dividends.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Fisher & Paykel Healthcare shares: Earnings outlook upgraded for FY27

Here's what the company expects to report for FY 2027.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Test Only

Pacific Edge FY26: Loss widens but Medicare draft boost lifts outlook

Pacific Edge’s FY26 loss grew, but US Medicare draft coverage for its diagnostic tests supports a more positive outlook going…

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

Why I'd buy CSL, Cochlear, and Pro Medicus shares

These are three ASX healthcare shares I would be happy to own for years.

Read more »

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Earnings Results

Sonic Healthcare share price in focus on FY26 profit jump and digital push

The healthcare company is paying total dividends of $1.08 per share in FY 2026.

Read more »

A man closely watches a clock.
Healthcare Shares

CSL shares are flying higher. Is it too late to buy?

CSL must now deliver faster earnings growth to justify its rally.

Read more »

Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.
Earnings Results

Telix Pharmaceuticals delivers robust half-year earnings and pipeline progress

The radiopharmaceuticals company has handed down its half-year results this morning.

Read more »